Pharmaceutical Preparations Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Pharmaceutical Preparations
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2019-02-14 | STML | Stemline Therapeutics Inc | Bergstein Ivan | CEO | S - Sale | $10.98 | -34,132 | 2,749,056 | -1% | -$374,769 | ||||||
2019-02-15 | AMRN | Amarin Corp Plcuk | Kalb Michael Wayne | SVP, CFO | S - Sale | $17.58 | -25,000 | 20,551 | -55% | -$439,525 | ||||||
| D | 2019-02-15 | AMPH | Amphastar Pharmaceuticals, Inc. | Peters William J | CFO, SVP, Treasurer | S - Sale+OE | $24.37 | -10,016 | 75,550 | -12% | -$244,090 | |||||
2019-02-13 | VERU | Veru Inc. | Steiner Mitchell Shuster | Pres, CEO, 10% | S - Sale | $1.52 | -4,650 | 7,929,662 | 0% | -$7,085 | ||||||
2019-02-15 | VERU | Veru Inc. | Fisch Harry | Dir, 10% | P - Purchase | $1.36 | +13,681 | 8,034,721 | 0% | +$18,654 | ||||||
| D | 2019-02-14 | BMRN | Biomarin Pharmaceutical Inc | Bienaime Jean Jacques | CEO | S - Sale+OE | $95.20 | -4,000 | 469,631 | -1% | -$380,800 | |||||
| D | 2019-02-14 | AMPH | Amphastar Pharmaceuticals, Inc. | Shandell Jason B. | Pres, GC | S - Sale+OE | $23.99 | -7,519 | 168,318 | -4% | -$180,381 | |||||
2019-02-13 | GWPH | Gw Pharmaceuticals Plc | Gover Justin D. | CEO | S - Sale | $12.50 | -22,620 | 370,445 | -6% | -$282,750 | ||||||
| M | 2019-02-13 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres,COB,CEO,CFO, 10% | P - Purchase | $0.25 | +151,000 | 6,767,360 | +2% | +$37,900 | |||||
| D | 2019-02-14 | ZTS | Zoetis Inc. | Lewis Clinton A. Jr. | EVP | S - Sale+OE | $91.96 | -6,125 | 39,387 | -13% | -$563,255 | |||||
| D | 2019-02-13 | RYTM | Rhythm Pharmaceuticals, Inc. | Gottesdiener Keith Michael | CEO, Pres | S - Sale+OE | $30.00 | -3,934 | 540,986 | -1% | -$118,020 | |||||
2019-02-12 | ENDV | Endonovo Therapeutics, Inc. | Collier Alan Brian | CEO | P - Purchase | $0.02 | +17,500 | 21,362,123 | 0% | +$390 | ||||||
2019-02-12 | ENDV | Endonovo Therapeutics, Inc. | Collier Alan Brian | CEO | P - Purchase | $0.02 | +213,000 | 42,664,246 | +1% | +$4,807 | ||||||
| D | 2019-02-14 | VTVT | Vtv Therapeutics Inc. | Perelman Ronald O | 10% | P - Purchase | $1.84 | +815,217 | 15,678,436 | +5% | +$1,499,999 | |||||
2019-02-13 | MYOK | Myokardia Inc | Sanofi | 10% | S - Sale | $37.66 | -4,168,899 | 0 | -100% | -$157,000,736 | ||||||
| D | 2019-02-12 | ZGNX | Zogenix, Inc. | Garner Cam L | Dir | S - Sale+OE | $46.85 | -12,405 | 40,843 | -23% | -$581,147 | |||||
| DM | 2019-02-12 | AMPH | Amphastar Pharmaceuticals, Inc. | Liawatidewi Yakob | SVP Corp Admin Center | S - Sale+OE | $23.86 | -8,868 | 42,252 | -17% | -$211,632 | |||||
| D | 2019-02-12 | MRK | Merck & Co., Inc. | Chattopadhyay Sanat | Exe V-P, Pres MMD | S - Sale+OE | $78.62 | -73,727 | 51,467 | -59% | -$5,796,306 | |||||
| D | 2019-02-13 | MRK | Merck & Co., Inc. | Weeks Wendell P | Dir | S - Sale+OE | $78.71 | -5,000 | 100 | -98% | -$393,548 | |||||
| D | 2019-02-14 | MRK | Merck & Co., Inc. | Karachun Rita A | SVP Fince-Global Controller | S - Sale+OE | $78.96 | -64,662 | 16,175 | -80% | -$5,105,951 | |||||
| D | 2019-02-12 | IONS | Ionis Pharmaceuticals Inc | O'Neil Patrick R. | SVP Legal, GC | S - Sale+OE | $59.50 | -275 | 19,673 | -1% | -$16,363 | |||||
| D | 2019-02-13 | IONS | Ionis Pharmaceuticals Inc | Crooke Stanley T | COB, CEO | S - Sale+OE | $60.09 | -46,904 | 800,557 | -6% | -$2,818,268 | |||||
2019-02-13 | IONS | Ionis Pharmaceuticals Inc | Geary Richard S | SVP, Development | S - Sale | $60.00 | -999 | 21,442 | -4% | -$59,940 | ||||||
2019-02-12 | SAGE | Sage Therapeutics, Inc. | Starr Kevin P | Dir | S - Sale | $0.00 | -0 | 302,817 | 0% | -$0 | ||||||
| M | 2019-02-12 | VRCA | Verrica Pharmaceuticals Inc. | Davidson Matt | 10% | S - Sale | $12.36 | -13,191 | 2,953,382 | 0% | -$163,013 | |||||
2019-02-12 | GBT | Global Blood Therapeutics, Inc. | Calhoun Lesley Ann | See Remarks | S - Sale | $50.45 | -354 | 1,032 | -26% | -$17,860 | ||||||
| M | 2019-02-12 | SYBX | Synlogic, Inc. | Miller Paul Francis | Chief Scientific Officer | S - Sale | $9.75 | -9,000 | 48,135 | -16% | -$87,750 | |||||
| M | 2018-12-21 | XBIT | Xbiotech Inc. | Rennes Fondation | 10% | P - Purchase | $9.25 | +112,300 | 3,698,282 | +3% | +$1,039,049 | |||||
| D | 2019-02-13 | TEVA | Teva Pharmaceutical Industries Ltd | De Notaristefani Carlo | EVP Global Operations | S - Sale+OE | $17.88 | -5,041 | 12,121 | -29% | -$90,108 | |||||
2019-02-13 | ENTA | Enanta Pharmaceuticals Inc | Gardiner Nathaniel S. | SVP, GC | S - Sale | $95.28 | -3,270 | 23,978 | -12% | -$311,562 | ||||||
| DM | 2019-02-11 | ENTA | Enanta Pharmaceuticals Inc | Or Yat Sun | SVP, CSO | S - Sale+OE | $89.52 | -33,981 | 310,673 | -10% | -$3,041,910 | |||||
| DM | 2019-02-11 | ENTA | Enanta Pharmaceuticals Inc | Golumbeski George | Dir | S - Sale+OE | $90.06 | -13,500 | 0 | -100% | -$1,215,853 | |||||
| M | 2019-02-11 | RTRX | Retrophin, Inc. | Reed Elizabeth E | SVP, GC, Corporate Secretary | S - Sale | $21.44 | -1,769 | 14,558 | -11% | -$37,927 | |||||
| DM | 2019-02-11 | ENTA | Enanta Pharmaceuticals Inc | Carter Bruce L A | Dir | S - Sale+OE | $90.01 | -7,734 | 0 | -100% | -$696,102 | |||||
| M | 2019-02-11 | RTRX | Retrophin, Inc. | Rote William E. | SVP, R, D | S - Sale | $21.44 | -1,985 | 16,007 | -11% | -$42,558 | |||||
| M | 2019-02-11 | RTRX | Retrophin, Inc. | Clague Laura | CFO | S - Sale | $21.44 | -2,033 | 10,000 | -17% | -$43,587 | |||||
| M | 2019-02-11 | RTRX | Retrophin, Inc. | Aselage Steve | CEO | S - Sale | $21.44 | -2,130 | 257,642 | -1% | -$45,667 | |||||
| A | 2018-04-30 | BMY | Bristol Myers Squibb Co | Paliwal Dinesh C | Dir | P - Purchase | $52.40 | +9,540 | 12,935 | +281% | +$499,896 | |||||
2019-02-11 | VRTX | Vertex Pharmaceuticals Inc / Ma | Sachdev Amit | EVP, CRO | S - Sale | $180.06 | -35,095 | 53,262 | -40% | -$6,319,216 | ||||||
2019-02-11 | VRTX | Vertex Pharmaceuticals Inc / Ma | Leiden Jeffrey M | CEO, Pres | S - Sale | $180.24 | -111,431 | 127,632 | -47% | -$20,083,804 | ||||||
2019-02-11 | VRTX | Vertex Pharmaceuticals Inc / Ma | Arbuckle Stuart A | EVP\Chief Commercial Officer | S - Sale | $180.21 | -33,073 | 39,004 | -46% | -$5,959,969 | ||||||
2019-02-11 | VRTX | Vertex Pharmaceuticals Inc / Ma | Altshuler David | EVP, Global Research, CSO | S - Sale | $180.22 | -32,956 | 37,177 | -47% | -$5,939,188 | ||||||
2019-02-11 | VRTX | Vertex Pharmaceuticals Inc / Ma | Parini Michael | EVP, CL, AO | S - Sale | $180.22 | -12,136 | 40,627 | -23% | -$2,187,190 | ||||||
2019-02-12 | LCI | Lannett Co Inc | Lepore Patrick G | Dir | P - Purchase | $8.93 | +25,000 | 117,895 | +27% | +$223,250 | ||||||
| D | 2019-02-12 | ZTS | Zoetis Inc. | Peck Kristin C | EVP | S - Sale+OE | $86.79 | -11,500 | 29,652 | -28% | -$998,085 | |||||
2019-02-11 | VRTX | Vertex Pharmaceuticals Inc / Ma | Silva Paul M | SVP, Interim CFO | S - Sale | $180.16 | -4,215 | 20,740 | -17% | -$759,367 | ||||||
2019-02-06 | GTBP | Gt Biopharma, Inc. | Cataldo Tony | Dir | S - Sale | $0.00 | -800,000 | 4,029,600 | -17% | -$800 | ||||||
| AD | 2018-12-12 | CORT | Corcept Therapeutics Inc | Belanoff Joseph K | CEO | S - Sale+OE | $19.01 | -217,115 | 2,164,195 | -9% | -$4,126,509 | |||||
| DM | 2019-02-08 | ARWR | Arrowhead Pharmaceuticals, Inc. | Given Bruce D | COO | S - Sale+OE | $16.04 | -242,834 | 670,856 | -27% | -$3,894,247 | |||||
| M | 2019-02-08 | XERS | Xeris Pharmaceuticals Inc | Flynn James E | Possible Member of 10% Group, 10% | S - Sale | $15.09 | -7,241 | 2,355,136 | 0% | -$109,251 | |||||
| M | 2019-02-07 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres,COB,CEO,CFO, 10% | P - Purchase | $0.41 | +3,000 | 6,616,360 | 0% | +$1,220 | |||||
2019-02-12 | GOSS | Gossamer Bio, Inc. | Cox Russell J. | Dir | P - Purchase | $16.00 | +7,200 | 7,200 | New | +$115,200 | ||||||
| D | 2019-02-12 | GOSS | Gossamer Bio, Inc. | Christian Waage | EVP, GC | P - Purchase | $16.00 | +1,550 | 527,174 | 0% | +$24,800 | |||||
| D | 2019-02-12 | GOSS | Gossamer Bio, Inc. | Giraudo Bryan | CFO | P - Purchase | $16.00 | +6,000 | 23,879 | +34% | +$96,000 | |||||
2018-09-10 | ETST | Earth Science Tech, Inc. | Majorca Group, Ltd. | 10% | S - Sale | $0.75 | -480,000 | 24,520,000 | -2% | -$360,000 | ||||||
2019-02-08 | ALPN | Alpine Immune Sciences, Inc. | Tiger Management L.L.C. | 10% | S - Sale | $5.85 | -25,000 | 137,728 | -15% | -$146,245 | ||||||
| M | 2019-02-07 | VRCA | Verrica Pharmaceuticals Inc. | Davidson Matt | 10% | S - Sale | $13.53 | -13,057 | 2,966,573 | 0% | -$176,676 | |||||
| D | 2019-02-08 | MRK | Merck & Co., Inc. | Brun Leslie A | Dir | S - Sale+OE | $77.22 | -3,052 | 1,948 | -61% | -$235,681 | |||||
| M | 2019-02-06 | ENDV | Endonovo Therapeutics, Inc. | Collier Alan Brian | CEO | P - Purchase | $0.03 | +38,000 | 21,131,623 | 0% | +$985 | |||||
2019-02-11 | LCI | Lannett Co Inc | Crew Timothy C | CEO | P - Purchase | $8.48 | +4,000 | 45,988 | +10% | +$33,920 | ||||||
2019-02-07 | GALT | Galectin Therapeutics Inc | Lewis Joel | Dir | P - Purchase | $4.48 | +1,000 | 65,133 | +2% | +$4,484 | ||||||
2019-02-08 | GALT | Galectin Therapeutics Inc | Freeman Kevin D | Dir | P - Purchase | $4.29 | +1,500 | 39,543 | +4% | +$6,428 | ||||||
| D | 2019-02-07 | CELG | Celgene Corp /de/ | Loughlin James J | Dir | S - Sale+OE | $87.29 | -23,466 | 40,436 | -37% | -$2,048,324 | |||||
| D | 2019-02-07 | CBAY | Cymabay Therapeutics, Inc. | Goldfischer Carl | Dir | S - Sale+OE | $9.02 | -11,675 | 0 | -100% | -$105,328 | |||||
| D | 2019-02-07 | SRPT | Sarepta Therapeutics, Inc. | Mahatme Sandesh | EVP, CFO, CBO | S - Sale+OE | $145.00 | -65,000 | 20,661 | -76% | -$9,425,000 | |||||
| D | 2019-02-06 | ARRY | Array Biopharma Inc | Lefkoff Kyle | Dir | S - Sale+OE | $20.60 | -35,000 | 57,720 | -38% | -$721,074 | |||||
| D | 2019-02-07 | FGEN | Fibrogen Inc | Schoeneck James A | Dir | S - Sale+OE | $57.17 | -2,000 | 27,700 | -7% | -$114,340 | |||||
| DM | 2019-02-07 | FGEN | Fibrogen Inc | Neff Thomas B | CEO | S - Sale+OE | $56.47 | -48,180 | 2,808,289 | -2% | -$2,720,677 | |||||
| D | 2019-02-06 | ARRY | Array Biopharma Inc | Robbins Andrew R | COO | S - Sale+OE | $20.02 | -239,626 | 59,994 | -80% | -$4,798,511 | |||||
| DM | 2019-02-06 | ARRY | Array Biopharma Inc | Haddock Jason | CFO | S - Sale+OE | $21.80 | -96,712 | 30,059 | -76% | -$2,108,541 | |||||
| D | 2019-02-07 | ARRY | Array Biopharma Inc | Saccomano Nicholas A | CSO | S - Sale+OE | $21.58 | -187,264 | 142,488 | -57% | -$4,041,756 | |||||
| D | 2019-02-07 | ARRY | Array Biopharma Inc | Squarer Ron | CEO | S - Sale+OE | $21.64 | -110,000 | 238,709 | -32% | -$2,380,015 | |||||
| D | 2019-02-06 | MGNX | Macrogenics Inc | Fust Matthew K | Dir | S - Sale+OE | $29.38 | -6,924 | 500 | -93% | -$203,427 | |||||
2019-02-06 | MGNX | Macrogenics Inc | Peters Jeffrey Stuart | GC | S - Sale | $30.00 | -68 | 202 | -25% | -$2,040 | ||||||
| D | 2019-02-06 | MGNX | Macrogenics Inc | Spitznagel Thomas | SVP, BPD, Manufacturing | S - Sale+OE | $30.00 | -1,770 | 0 | -100% | -$53,100 | |||||
2019-02-06 | PTGX | Protagonist Therapeutics, Inc | Patel Dinesh V Ph D | Pres, CEO | S - Sale | $7.74 | -10,909 | 357,264 | -3% | -$84,410 | ||||||
| M | 2019-02-06 | VERU | Veru Inc. | Steiner Mitchell Shuster | Pres, CEO, 10% | S - Sale | $1.50 | -10,455 | 7,934,312 | 0% | -$15,724 | |||||
2019-02-06 | PTGX | Protagonist Therapeutics, Inc | Liu David Y | Chief Scientific Officer | S - Sale | $7.74 | -3,821 | 37,007 | -9% | -$29,562 | ||||||
2019-02-07 | SPPI | Spectrum Pharmaceuticals Inc | McGahan Keith M | SVP, GC | S - Sale | $11.03 | -2,496 | 104,887 | -2% | -$27,541 | ||||||
2019-02-06 | PTGX | Protagonist Therapeutics, Inc | Shames Richard S. | Chief Medical Officer | S - Sale | $7.74 | -2,778 | 24,178 | -10% | -$21,506 | ||||||
2019-02-08 | SAGE | Sage Therapeutics, Inc. | Kanes Stephen | Chief Medical Officer | S - Sale | $150.00 | -22,948 | 941 | -96% | -$3,442,200 | ||||||
2019-02-06 | NATR | Natures Sunshine Products Inc | Hughes Kristine F | Dir | S - Sale | $7.96 | -3,000 | 650,722 | 0% | -$23,880 | ||||||
| DM | 2019-02-06 | VCNX | Vaccinex, Inc. | Royer Scott E. | CFO | P - Purchase | $4.98 | +2,000 | 3,999 | +100% | +$9,968 | |||||
2019-02-07 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale | $7.28 | -1,500 | 84,067 | -2% | -$10,920 | ||||||
| M | 2019-02-06 | MSLP | Musclepharm Corp | Wynnefield Partners Small Cap Value LP I | 10% | P - Purchase | $0.40 | +100,000 | 1,871,305 | +6% | +$40,000 | |||||
2019-02-04 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres | P - Purchase | $0.03 | +4,000 | 26,703,897 | 0% | +$103 | ||||||
2019-02-05 | ARWR | Arrowhead Pharmaceuticals, Inc. | Given Bruce D | COO | S - Sale | $14.48 | -22,500 | 847,856 | -3% | -$325,800 | ||||||
| M | 2019-02-05 | XERS | Xeris Pharmaceuticals Inc | Flynn James E | Possible Member of 10% Group, 10% | S - Sale | $15.02 | -14,807 | 2,362,377 | -1% | -$222,443 | |||||
2019-02-05 | AKAO | Achaogen, Inc. | Dorling Janet | Chief Commercial Officer | S - Sale | $1.35 | -818 | 285,801 | 0% | -$1,104 | ||||||
| D | 2019-02-05 | BMRN | Biomarin Pharmaceutical Inc | Bienaime Jean Jacques | CEO | S - Sale+OE | $98.63 | -4,000 | 469,791 | -1% | -$394,520 | |||||
2019-02-05 | PRTK | Paratek Pharmaceuticals, Inc. | Woodrow Adam | VP, Chief Commercial Officer | S - Sale | $6.77 | -3,331 | 144,694 | -2% | -$22,551 | ||||||
2019-02-05 | PRTK | Paratek Pharmaceuticals, Inc. | Pagan Douglas W. | CFO | S - Sale | $6.77 | -2,495 | 134,057 | -2% | -$16,891 | ||||||
2019-02-05 | PRTK | Paratek Pharmaceuticals, Inc. | Haskel William M. | SVP, Sec., GC | S - Sale | $6.77 | -1,331 | 112,220 | -1% | -$9,011 | ||||||
| D | 2019-02-05 | ARRY | Array Biopharma Inc | Oltmans Curtis Gale | GC | S - Sale+OE | $20.00 | -40,000 | 15,021 | -73% | -$800,000 | |||||
| D | 2019-02-05 | DCPH | Deciphera Pharmaceuticals, Inc. | Bristol James Arthur | Dir | S - Sale+OE | $28.02 | -2,595 | 0 | -100% | -$72,704 | |||||
2019-02-05 | INSM | Insmed Inc | Altomari Alfred | Dir | S - Sale | $25.00 | -5,500 | 36,942 | -13% | -$137,500 | ||||||
| D | 2019-02-05 | AMPH | Amphastar Pharmaceuticals, Inc. | Zhou Rong | EVP, Production Center | S - Sale+OE | $23.00 | -4,289 | 156,698 | -3% | -$98,647 | |||||
| D | 2019-02-06 | VRTX | Vertex Pharmaceuticals Inc / Ma | Silva Paul M | SVP, Interim CFO | S - Sale+OE | $193.00 | -1,289 | 12,818 | -9% | -$248,777 | |||||
| D | 2019-02-05 | DCPH | Deciphera Pharmaceuticals, Inc. | Taylor Michael Douglas | Pres, CEO | S - Sale+OE | $28.01 | -1,700 | 0 | -100% | -$47,611 | |||||
| D | 2019-02-05 | AMPH | Amphastar Pharmaceuticals, Inc. | Liawatidewi Yakob | SVP Corp Admin Center | S - Sale+OE | $23.18 | -11,397 | 42,252 | -21% | -$264,167 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |